A longitudinal assessment of antimicrobial susceptibility among important pathogens collected as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) in France between 2004 and 2012

Antimicrobial Resistance and Infection Control

Volumn 3, Issue 1, 2014, Pages

  Cattoir, Vincent ^a   Dowzicky, Michael J ^b  

^a CAEN UNIVERSITY HOSPITAL   (France)

^b PFIZER INC   (United States)

Author keywords

Antimicrobial resistance; Antimicrobial surveillance; France; MDR; Multidrug resistance; Tigecycline

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZITHROMYCIN; CARBAPENEM DERIVATIVE; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CLARITHROMYCIN; CLINDAMYCIN; ERYTHROMYCIN; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MEROPENEM; MINOCYCLINE; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; DISEASE SURVEILLANCE; ENTEROBACTER; ENTEROBACTER AEROGENES; ENTEROBACTER CLOACAE; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; FRANCE; HAEMOPHILUS INFLUENZAE; HUMAN; IN VITRO STUDY; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; LONGITUDINAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SERRATIA MARCESCENS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS AGALACTIAE;

EID: 84929625250     PISSN: None     EISSN: 20472994     Source Type: Journal    
DOI: 10.1186/2047-2994-3-36     Document Type: Article

References (24)

1. Dumartin C, L'Hériteau F, Péfau M, Bertrand X, Jarno P, Boussat S, Angora P, Lacavé L, Saby K, Savey A, Nguyen F, Carbonne A, Rogues AM: Antibiotic use in 530 French hospitals: results from a surveillance network at hospital and ward levels in 2007. J Antimicrob Chemother 2010, 65:2028-2036.
2. European Centre for Disease Prevention and Control: Antimicrobial resistance surveillance in Europe 2012. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC; 2013.
3. European Centre for Disease Prevention and Control: Antimicrobial resistance interactive database (EARS-Net). [http://www.ecdc.europa.eu/en/healthtopics/antimicrobial_resistance/database/Pages/database.aspx]
4. Fournier S, Brun-Buisson C, Jarlier V: Twenty years of antimicrobial resistance control programme in a regional multi hospital institution, with focus on emerging bacteria (VRE and CPE). Antimicrob Resist Infect Control 2012, 13:1-9.
5. Pfizer Inc. (Wyeth Pharmaceuticals): Tygacil® Product Insert. http://www.pfizerpro.com/hcp/tygacil
6. Rodloff AC, Leclercq R, Debbia EA, Cantón R, Oppenheim BA, Dowzicky MJ: Comparative analysis of antimicrobial susceptibility among organisms from France, Germany, Italy, Spain and the UK as part of the tigecycline evaluation and surveillance trial. Clin Microbiol Infect 2008, 14:307-314.
7. Nørskov-Lauritsen N, Marchandin H, Dowzicky MJ: Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007). Int J Antimicrob Agents 2009, 34:121-130.
8. Clinical and Laboratory Standards Institute (CLSI): Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, Approved Standard. 8th ed. Document M7-A8. Wayne, PA: CLSI; 2009.
9. European Committee on Antimicrobial Susceptibility Testing: Clinical breakpoints. [http://www.eucast.org/clinical_breakpoints/]
10. Clinical and Laboratory Standards Institute (CLSI): Performance Standards for Antimicrobial Susceptibility Testing: 23rd ed. Document M100-S23. Wayne, PA: CLSI; 2013.
11. Kassis-Chikhani N, Saliba F, Carbonne A, Neuville S, Decre D, Sengelin C, Guerin C, Gastiaburu N, Lavigne-Kriaa A, Boutelier C, Arlet G, Samuel D, Castaing D, Dussaix E, Jarlier V: Extended measures for controlling an outbreak of VIM-1 producing imipenem-resistant Klebsiella pneumoniae in a liver transplant centre in France, 2003-2004. Euro Surveill 2010., 15
12. Carbonne A, Thiolet JM, Fournier S, Fortineau N, Kassis-Chikhani N, Boytchev I, Aggoune M, Seguier JC, Senechal H, Tavolacci MP, Coignard B, Astagneau P, Jarlier V: Control of a multi-hospital outbreak of KPC-producing Klebsiella pneumoniae type 2 in France, September to October 2009. Euro Surveill 2010., 15:
13. Ayraud-Thévenot S, Huart C, Mimoz O, Taouqi M, Laland C, Bousseau A, Castel O: Control of multi-drug-resistant Acinetobacter baumannii outbreaks in an intensive care unit: feasibility and economic impact of rapid unit closure. J Hosp Infect 2012, 82:290-292.
14. Parer S, Lotthé A, Chardon P, Poncet R, Jean-Pierre H, Jumas-Bilak E: An outbreak of heterogeneous glycopeptide-intermediate Staphylococcus aureus related to a device source in an intensive care unit. Infect Control Hosp Epidemiol 2012, 33:167-174.
15. Bourdon N, Fines-Guyon M, Thiolet JM, Maugat S, Coignard B, Leclercq R, Cattoir V: Changing trends in vancomycin-resistant enterococci in French hospitals, 2001-08. J Antimicrob Chemother 2011, 66:713-721.
16. Kalil AC, Klompas M, Haynatzki G, Rupp ME: Treatment of hospital-acquired pneumonia with linezolid or vancomycin: a systematic review and meta-analysis. BMJ Open 2013, 3:e003912.
17. Lee YT, Tsao SM, Hsueh PR: Clinical outcomes of tigecycline alone or in combination with other antimicrobial agents for the treatment of patients with healthcare-associated multidrug-resistant Acinetobacter baumannii infections. Eur J Clin Microbiol Infect Dis 2013, 32:1211-1220.
18. Carbonne A, Arnaud I, Maugat S, Marty N, Dumartin C, Bertrand X, Bajolet O, Savey A, Fosse T, Eveillard M, Sénéchal H, Coignard B, Astagneau P, Jarlier V, MDRB Surveillance National Steering Group (BMR-Raisin): National multidrug-resistant bacteria (MDRB) surveillance in France through the RAISIN network: a 9 year experience. J Antimicrob Chemother 2013, 68:954-959.
19. Marcadé G, Brisse S, Bialek S, Marcon E, Leflon-Guibout V, Passet V, Moreau R, Nicolas-Chanoine MH: The emergence of multidrug-resistant Klebsiella pneumoniae of international clones ST13, ST16, ST35, ST48 and ST101 in a teaching hospital in the Paris region. Epidemiol Infect 2013, 141:1705-1712.
20. Gbaguidi-Haore H, Dumartin C, L'Hériteau F, Péfau M, Hocquet D, Rogues AM, Bertrand X, ATB-RAISIN Network Steering Committee: Antibiotics involved in the occurrence of antibiotic-resistant bacteria: a nationwide multilevel study suggests differences within antibiotic classes. J Antimicrob Chemother 2013, 68:461-470.
21. Kempf M, Baraduc R, Bonnabau H, Brun M, Chabanon G, Chardon H, Croizé J, Demachy MC, Donnio PY, Dupont P, Fosse T, Gibel L, Gravet A, Grignon B, Hadou T, Hamdad F, Joly-Guillou ML, Koeck JL, Maugein J, Péchinot A, Ploy MC, Raymond J, Ros A, Roussel-Delvallez M, Segonds C, Vergnaud M, Vernet-Garnier V, Lepoutre A, Gutmann L, Varon E, et al.: Epidemiology and antimicrobial resistance of Streptococcus pneumoniae in France in 2007: data from the pneumococcus surveillance network. Microb Drug Resist 2011, 17:31-36.
22. Marcadé G, Micol JB, Jacquier H, Raskine L, Donay JL, Nicolas-Viaud S, Rouveau M, Ribaud P, Dombret H, Leclercq R, Cambau E: Outbreak in a haematology unit involving an unusual strain of glycopeptide-resistant Enterococcus faecium carrying both vanA and vanB genes. J Antimicrob Chemother 2014, 69:500-505.
23. Bérenger R, Bourdon N, Auzou M, Leclercq R, Cattoir V: In vitro activity of new antimicrobial agents against glycopeptide-resistant Enterococcus faecium clinical isolates from France between 2006 and 2008. Med Mal Infect 2011, 41:405-409.
24. Dabernat H, Delmas C: Epidemiology and evolution of antibiotic resistance of Haemophilus influenzae in children 5 years of age or less in France, 2001-2008: a retrospective database analysis. Eur J Clin Microbiol Infect Dis 2012, 31:2745-2753.